ALZN
Income statement / Annual
Last year (2025), Alzamend Neuro Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Alzamend Neuro Inc's net income was -$4.51 M.
See Alzamend Neuro Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
04/30/2025 |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$50.74 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$50.74 K
|
-$50.74 K
|
-$23.07 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$1.41 M
|
$6.46 M
|
$7.45 M
|
$5.20 M
|
$1.31 M
|
$1.07 M
|
$3.70 M
|
$323.40 K
|
$275.05 K
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$3.48 M
|
$6.68 M
|
$7.12 M
|
$3.64 M
|
$3.36 M
|
$1.31 M
|
$545.12 K
|
$942.51 K
|
$69.46 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$742.60 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$29.91 K
|
$330.84 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.03 M
|
$3.48 M
|
$7.43 M
|
$7.12 M
|
$3.64 M
|
$3.36 M
|
$1.31 M
|
$575.03 K
|
$1.27 M
|
$69.46 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.45 M
|
$9.94 M
|
$14.87 M
|
$12.32 M
|
$4.95 M
|
$4.42 M
|
$5.01 M
|
$898.43 K
|
$1.55 M
|
$69.46 K
|
| Cost And Expenses |
$4.50 M
|
$9.94 M
|
$14.87 M
|
$12.32 M
|
$4.95 M
|
$4.42 M
|
$5.01 M
|
$898.43 K
|
$1.55 M
|
$69.46 K
|
| Interest Income |
$0.00
|
$0.00
|
$7.70
|
$46.52
|
$1.71 K
|
$13.93 K
|
$146.39 K
|
$33.23 K
|
$21.50 K
|
$0.00
|
| Interest Expense |
$18.03 K
|
$10.10 K
|
$7.70 K
|
$46.52 K
|
$158.80 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$50.74 K
|
$50.74 K
|
$23.07 K
|
$3.55 K
|
$4.95 M
|
$4.42 M
|
$5.01 M
|
$898.43 K
|
$1.55 M
|
$69.46 K
|
| EBITDA |
-$4.45 M |
-$9.89 M |
-$14.85 M |
-$12.32 M |
-$4.95 M |
$14.00 K |
-$5.01 M |
$7.34 K |
-$21.50 K |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$18.03 K
|
-$10.10 K
|
-$7.70 K
|
-$42.52 K
|
-$94.68 K
|
$13.93 K
|
$146.39 K
|
-$33.23 K
|
-$21.50 K
|
$0.00
|
| Income Before Tax |
-$4.51 M
|
-$9.95 M
|
-$14.88 M
|
-$12.36 M
|
-$5.05 M
|
-$4.41 M
|
-$4.86 M
|
-$932.00 K
|
-$1.57 M
|
-$69.46 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$4.51 M
|
-$9.95 M
|
-$14.88 M
|
-$12.36 M
|
-$5.05 M
|
-$4.41 M
|
-$4.86 M
|
-$932.00 K
|
-$1.57 M
|
-$69.46 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-11.32 |
-132.33 |
-205.97 |
-187.31 |
-93.78 |
-83.56 |
-111.56 |
-27.71 |
-73.59 |
0 |
| EPS Diluted |
-11.32 |
-132.33 |
-205.97 |
-187.31 |
-93.78 |
-83.56 |
-111.56 |
-27.71 |
-73.59 |
0 |
| Weighted Average Shares Out |
$398.00 K
|
$75.00 K
|
$72.00 K
|
$65.00 K
|
$53.00 K
|
$52.00 K
|
$43.00 K
|
$33.00 K
|
$21.00 K
|
$0.00
|
| Weighted Average Shares Out Diluted |
$450.80 K
|
$75.17 K
|
$72.24 K
|
$66.00 K
|
$53.82 K
|
$52.78 K
|
$43.59 K
|
$33.62 K
|
$21.33 K
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
